Rao Rajeev, Panghate Atul, Chandanwale Ajay, Sardar Indrajeet, Ghosh Mriganka, Roy Modan, Banerjee Bireswar, Goswami Ankur, Kotwal Prakash P
Department of Orthopedics, Jubilee Missions Medical College, Thrissur, India.
Asian Spine J. 2012 Jun;6(2):115-22. doi: 10.4184/asj.2012.6.2.115. Epub 2012 May 31.
We performed a multicentric, randomized, comparative clinical trial. Eligible patients were randomly assigned to receive 150 mg of Tolperisone thrice daily or 8 mg of Thiocolchicoside twice daily for 7 days.
To assess the efficacy and tolerability of Tolperisone in comparison with Thiocolchicoside in the treatment of acute low back pain with spasm of spinal muscles.
No head on clinical trial of Tolperisone with Thiocolchicoside is available and so this study is done.
The assessment of muscle spasm was made by measuring the finger-to-floor distance (FFD), articular excursion in degrees on performing Lasegue's maneuver and modified Schober's test. Assessment of pain on movement and spontaneous pain (pain at rest) of the lumbar spine was made with the help of visual analogue scale score.
The improvement in articular excursion on Lasegue's maneuver was significantly greater on day 3 (p = 0.017) and day 7 (p = 0.0001) with Tolperisone as compared to Thiocolchicoside. The reduction in FFD score was greater on day 7 (p = 0.0001) with Tolperisone. However there was no significant difference in improvement in Schober's test score on day 3 (p = 0.664) and day 7 (p = 0.192). The improvement in pain score at rest and on movement was significantly greater with Tolperisone ((p) = 0.0001).
Tolperisone is an effective and well tolerated option for treatment of patients with skeletal muscle spasm associated with pain.
我们进行了一项多中心、随机、对照临床试验。符合条件的患者被随机分配,分别接受每日三次、每次150毫克托哌酮或每日两次、每次8毫克硫代秋水仙碱治疗,为期7天。
评估托哌酮与硫代秋水仙碱相比,在治疗伴有脊柱肌肉痉挛的急性下背痛方面的疗效和耐受性。
目前尚无托哌酮与硫代秋水仙碱的直接对比临床试验,因此开展了本研究。
通过测量手指到地面的距离(FFD)、进行拉塞格试验时关节活动度的度数以及改良的肖伯试验来评估肌肉痉挛情况。借助视觉模拟量表评分评估腰椎运动时的疼痛和自发痛(静息痛)。
与硫代秋水仙碱相比,托哌酮治疗组在第3天(p = 0.017)和第7天(p = 0.0001)拉塞格试验中关节活动度的改善显著更大。托哌酮治疗组在第7天FFD评分的降低幅度更大(p = 0.0001)。然而,在第3天(p = 0.664)和第7天(p = 0.192),肖伯试验评分的改善没有显著差异。托哌酮治疗组在静息和运动时疼痛评分的改善显著更大(p = 0.0001)。
托哌酮是治疗伴有疼痛的骨骼肌痉挛患者的一种有效且耐受性良好的选择。